Kindstar Globalgene Technology, Inc. (9960.HK)
HKSE · HKD · Healthcare · Diagnostics & Research
HK$0.895 (+3.47%) as of
Key statistics
- Market cap
- 889.41M
- Forward P/E
- 7.46
- EPS (TTM)
- -0.040
- Dividend yield
- 10.56%
- 52-week range
- 0.855 – 1.360
- Beta
- 0.62
- Revenue (TTM)
- 950.26M
- Profit margin
- -4.37%
- Volume
- 101.00k
About Kindstar Globalgene Technology, Inc.
Kindstar Globalgene Technology, Inc., an investment holding company, provides clinical testing services in the People's Republic of China and Mainland China. It operates through nine segments: Hematology Testing. Genetic Diseases and Rare Diseases, Infectious Diseases, Oncology, Neurology, Maternity-Related Diseases, Routine Testing, CROs and R&D Project, and Others. The company offers esoteric testing services for hematology, oncology, neuroscience and infectious diseases. It also engages in product development and technical services; reagent development and sales; car-t treatment; and E-commerce services. The company's research and development projects, including molecular biology detection, flow cytometry detection, cytogenetic detection, and pathological detection technologies. Kindstar Globalgene Technology, Inc. was founded in 2003 and is headquartered in Wuhan, the People's Republic of China.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Wuhan, China
- Employees
- 2,999
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.